A study of diagnostic value of Golgi protein GP73 and its genetic assay in primary hepatic carcinoma

Technology in Cancer Research and Treatment

Volumn 10, Issue 3, 2011, Pages 287-294

  Shi, Y ^a   Chen, J ^a   Li, L ^a   Sun, Z ^a   Zen, L ^a   Xu, S ^a   Zhang, Y ^a   Zhang, L ^b  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b Beijing Modern Gaoda Biotechnology Co Ltd   (China)

Author keywords

Alpha fetoprotein; GP73; GP73 mRNA; Primary hepatic carcinoma

Indexed keywords

ALPHA FETOPROTEIN; GP73 PROTEIN; MESSENGER RNA; PLASMA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ANALYSIS; HEPATITIS; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; LIVER; LIVER CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

EID: 79955547872     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.7785/tcrt.2012.500205     Document Type: Article

References (18)

1. Huang, H. C., Zheng, S., VanBuren, V., Zhao, Z. Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 9, 219-230 (2010).
2. Eddy, J. A., Sung, J., Genman, D., Price, N. D. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat 9, 149-159 (2010).
3. Spangenberg, H. C., Thimme, R., Blum, H. E., Serum markers of hepatocellular carcinoma. Semin Liver Dis 26, 385-390 (2006).
4. Marrero, J., Romano, P. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43, 1007-1012 (2005).
5. Mao, Y., Yang, H., Xu, H., Lu, X., Sang, X., Du, S., Zhao, H., Chen, W., Xu, Y., Chi, T., Yang, Z., Cai, J., Li, H., Chen, J., Zhang, S., Mohanti, S. R., Lopez-Soler, R., Millis, J. M., Huang, J., Zhang, H. Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 59, 1687-1693 (2010).
6. Yamaoto, K., Imamura, H., Matsuyama, Y., Kume, Y., Kume, Y., Ikeda, H., Norman, G. L., Shums, Z., Aoki, T., Hasegawa, K., Beck, Y., Sugawara, Y., Kakudo, N. AFP, AFP-L3, DCP and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Gastroenterol 45, 1272-1282 (2010).
7. Hanabata, M., Ohyanagi, H., Saitoh, Y., Itoh, H. Immunohistochemical study on hepatic tumors-KM01 stains compared with AFP, CEA, CA19-9 and RAS P21. Kobe J Med Sci 37, 81-96 (1991).
8. Li, C. X., Zhang, Y., Gao, L. Analysis of combinated transcatheter hepatic artery chemoembolization and factors affecting the prognosis in patients with primary hepatic carcinoma. Zhonghua Zhong Liu Za Zhi 28, 942-945 (2006).
9. Bjerner, J., Hogetveitm, A., Wold Akselberg, K., Vangsnes, K., Paus, E., Bjoro, T., Bormer, OP., Nustad, K. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study. Scand J Clin Lab Invest 68, 703-713 (2008).
10. Zhang, L., Li, S. N., Wang, X. N. CEA and AFP expression in human hepatoma cells transfected with antisense IGFI-gene. World J Gastroenterol 4, 30-32 (1998).
11. Maussier, M. L., Valenza, V., Schinco, G., Galli, G. AFP, CEA, CA 19-9 and TPA in hepatocellular carcinoma. Int J Biol Markers 5, 21-126 (1990).
12. Maestranzi, S, Przenmioslor, R., Mirchell, H., Sherwood, R. A. The effect of benign and malignant liver disease on the tumor markers CA19-9 and CEA. Ann Clin Biochem 35, 99-103 (1998)
13. Kladney, R. D., Bulla, G. A., Guo, L., Mason, A. L., Tollefson, A. E., Simon, D. J., Koutoubi, Z., Fimmel, C. J. GP73, a novel golgi-localized protein upregulated by viral infection. Gene 249, 53-65 (2000).
14. Kladney, R. D., Xiaoyen, C., Bulla, G. A., Brunt, E. M., Fimmel, C. J. Expression of GP73, a resident golgi membrane protein, in viral and non-viral liver disease. Hepatology 35,1431-1440 (2002).
15. Iftikhar, R., Kladney, R. D., Havlioglu, N., Schmitt-Graff, A., Gusmirovic, I., Solomon, H., Luxon, B. A., Bacon, B. R., Fimmel, C. J, Disease and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 99, 1087-1095 (2004).
16. Maitra, A., Thuluvath, P. J, GP73 and liver disease, a (Golgi) complex enigma. Am J Gastroenterol 99, 1096-1098 (2004).
17. Block, T. M., Comunale, M. A., Lowman, M., Steel, L. F., Romano, P. R., Fimmel, C., Tennant, B. C., London, W. T., Evans, A. A., Blumberg, B. S., Dwek, R.A, Mattu, T. S., Mehta, A. S. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 102, 779-784 (2005).
18. Hu, J. S., Wu, D. W., Liang, S., Miao, X. Y. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol, Humana Press Inc 4. (2009).